#United States #New York #Securities Fraud #Pomerantz LLP #Novartis AG

Investor Alert: Pomerantz Law Firm Investigates Novartis AG

Pomerantz LLP, a leading law firm specialized in securities class action litigation, has announced its investigation focusing on potential claims on behalf of investors concerning Novartis AG (NYSE: NVS). This comes in light of a recent news release from Novartis which sparked significant concern among its shareholders.

On September 8, 2026, Novartis disclosed that the global Phase III HARBOR study regarding del-desiran, aimed at treating patients with myotonic dystrophy type 1 (DM1), yielded disappointing results. The data indicated there was no statistically significant improvement when comparing the drug to a placebo in the primary measurement known as video hand opening time (vHOT), an innovative metric used to assess hand myotonia. This announcement directly impacted Novartis's American Depositary Share (ADS) prices, which plummeted by $22.29—or 13.93%—closing at $137.70 per ADS the same day.

The firm seeks to determine whether Novartis, along with certain officers or directors, engaged in securities fraud or other unlawful business practices that may have affected investors. Such actions, if proven true, can lead to serious consequences for both the company and implicated individuals. What is critical for investors is to ascertain whether they were misled or if significant information was withheld that could influence their investment decisions.

Pomerantz LLP, established over 85 years ago and renowned in the field of securities class actions, aims to protect the rights of those affected by corporate misconduct and fraud. Founder Abraham L. Pomerantz, also known as the dean of the class action bar, set a high standard for legal advocacy in this area. The firm has consistently recovered substantial awards for class members impacted by securities fraud and breaches of fiduciary duty.

In view of the serious implications of the investigations for both Novartis and its investors, it's crucial for affected shareholders to consider their options moving forward. Pomerantz LLP has advised that investors who wish to join the class action should contact Danielle Peyton at [email protected] or call at 646-581-9980, extension 7980. They welcome the opportunity to offer guidance and support to investors navigating these challenging circumstances.

As developments unfold, stakeholders are reminded of the importance of staying informed about the investigation’s progress. Transparency in such matters is essential not only for accountability but also for maintaining public trust in corporate governance and the healthcare sector at large.

Overall, Pomerantz LLP’s investigation reflects a broader commitment within the legal community to address potential injustices stemming from corporate operations and ensure that investors are not left to shoulder losses without access to recourse. Investors are encouraged to act promptly as the investigation progresses and to seek legal counsel on their rights and potential actions related to Novartis AG.

For more information about Pomerantz LLP and their services, please visit www.pomlaw.com.

Contact Information:
Danielle Peyton
Pomerantz LLP
Email: [email protected]
Phone: 646-581-9980 ext. 7980